Telix Pharmaceuticals
(ASX:TLX) today announced that Dr. David Cade has joined the Telix executive leadership team in the role of Chief Business Officer and Head of Investor Relations.
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on “molecularly-targeted radiation” (MTR), has
David brings over 20 years of significant commercial, clinical and public company experience to Telix. Notable prior executive roles include Chief Medical Officer at Cochlear and Sirtex, where his responsibilities included not only clinical strategy but also commercial and investorfacing aspects.
Shares in Telix Pharmaceuticals
(ASX:TLX) closed 0.75 per cent higher on Friday.
